Psychedelics are set to become the next major innovation in mental healthcare. Despite the large flow of investment into this area, the development of psychedelic drugs is not without its hurdles. In this episode, we’ll get an introduction to the challenges surrounding the development of psychedelic drugs for mental healthcare, including clinical trial design, manufacture and commercialization. Participants in this episode are Adrienne Rivlin and Andre Valente, partners in L.E.K. Consulting’s London Office, and guest Tom McDonald, from Clerkenwell Health.

Interested in learning more? We updated our analysis of investments entering the psychedelics space. Here’s what it reveals about funding trends in 2022

Subscribe to our podcast Insight Exchange
Insight Exchange logo
If you’re a growth investor, an advanced student, an employee, a researcher, an executive, an entrepreneur, an inventor or a board member, we invite you to join us for Insight Exchange™.

Related Insights